Rossella Brusa

Rossella Brusa is an experienced medical professional specializing in dermatology and immunology, currently serving as a Medical Advisor and MSL Team Lead at Almirall since January 2020, focusing on anti-IL23 biological drug tildrakizumab and managing a team of MSLs across Italy. Prior to this role, Rossella held the position of Medical Science Liaison for Immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson from November 2015 to January 2020, emphasizing medical affairs related to ustekinumab and stakeholder partnerships. Rossella's career also includes significant positions at Novartis and Schering-Plough Research Institute, where responsibilities encompassed drug discovery and development in areas such as chronic pain and neurodegenerative disorders. Educational credentials include a PhD in Pharmacology and Toxicology and a degree in biology from Università degli Studi di Torino.